Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels

Abstract

Purpose We aimed to investigate the prognostic value of serum β2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system.Materials and Methods A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum β2-microglobulin levels. A risk-stratifying classification system incorporating serum β2-microglobulin levels was proposed and validated in an independent validation cohort (n=60).Results The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum β2-microglobulin levels (> 2 mg/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.01 for both). Serum β2-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum β2-microglobulin level (> 2 mg/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum β2-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes.Conclusion Serum β2-microglobulin level is an independent prognostic factor for BL patients. The proposed β2-microglobulin–based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients.

A novel clinical immune‐related prognostic model predicts the overall survival of mantle cell lymphoma

“…18 B2M is used as a predictive factor for tumor responsiveness to treatment and relapse, and the prognostic value of B2M in multiple hematological disorders was investigated in previous studies. [18][19][20] Previous studies confirmed the use of B2M as a prognostic and treatment failure factor in MCL. 21,22 Consistent with previous findings, B2M was an important component in our prognostic model.…”

“…The B2M level may be an immunological risk marker associated with survival 18 . B2M is used as a predictive factor for tumor responsiveness to treatment and relapse, and the prognostic value of B2M in multiple hematological disorders was investigated in previous studies 18–20 . Previous studies confirmed the use of B2M as a prognostic and treatment failure factor in MCL 21,22 .…”

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

“…KPS is generally completed at the time of admission assessment, which can easily reflect the patients' physical condition. b2-MG, which reflects the patient's tumor burden, can be obtained by peripheral blood tests (37)(38)(39), while SIRI can be calculated by complete blood count. Our study has shown that the four variables of Xijing model are all related to the prognosis of PCNSL patients.…”

Tuberculosis combined with Burkitt lymphoma in a kidney transplant recipient: A case report and literature review

“…[ 17 ] In addition, LDH and β2-MG are often present with varying degrees of elevation. [ 18 , 19 ] Positive EBV nucleic acid and elevated indicators such as lactate dehydrogenase and β2-MG were seen during the course of the disease. A case report [ 20 ] describes a 15-year-old boy, 3.5 years post-transplant with chronic EBV viremia, whose urinary CXCL10/Cr level increased acutely to 79.43 ng/mmol, 0.8 months prior to onset of BL.…”